Ciena R&D decreased by 3.3% to $221.46M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 14.9%, from $192.66M to $221.46M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 12.1% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $110.25M | $146.23M | $147.45M | $148.41M | $159.32M | $150.03M | $166.90M | $181.73M | $189.99M | $189.39M | $189.44M | $187.27M | $195.38M | $188.89M | $195.96M | $192.66M | $214.87M | $211.90M | $228.90M | $221.46M |
| QoQ Change | — | +32.6% | +0.8% | +0.6% | +7.4% | -5.8% | +11.2% | +8.9% | +4.5% | -0.3% | +0.0% | -1.1% | +4.3% | -3.3% | +3.7% | -1.7% | +11.5% | -1.4% | +8.0% | -3.3% |
| YoY Change | — | — | — | — | +44.5% | +2.6% | +13.2% | +22.5% | +19.2% | +26.2% | +13.5% | +3.0% | +2.8% | -0.3% | +3.4% | +2.9% | +10.0% | +12.2% | +16.8% | +14.9% |